EU welcomes the debut of Zemcelpro, a revolutionary blood cord expansion therapy

The European Commission has made a significant stride in the field of cancer therapeutics by granting conditional marketing authorization for ExCellThera's Zemcelpro (UM171 cell therapy). This innovative treatment, designed for adult patients with blood cancers who lack a suitable donor, promises to increase transplant access in cases where no matched donor is available.

Zemcelpro operates by utilising UM171, a small molecule that promotes stem cell self-renewal, to expand the number of stem cells while keeping them functionally intact. The expanded product contains two components: CD34+ cells that have been grown with UM171, and unmodified CD34 cells, both taken from the same cord blood unit.

This approach sets Zemcelpro apart from other cord blood expansion strategies that have been explored over the past decade. While many strategies have not progressed to late-stage clinical trials, Zemcelpro's improved cellular resilience contributes to durable engraftment, lowers the risk of graft failure, and may reduce complications associated with delayed immune recovery.

Notably, Zemcelpro is not the first cord blood expansion therapy to be approved worldwide. Gamida Cell's Omidubicel was approved in the U.S. in 2023. However, Zemcelpro's key differentiator lies in UM171's ability to amplify a more primitive stem cell population, potentially leading to more durable long-term clinical benefits.

ExCellThera's CEO, David Millette, believes Zemcelpro has the potential to be a best-in-class treatment option for high-risk leukemias and myelodysplasias. The company is preparing filings in key jurisdictions, including the U.S., where a phase 3 trial is already underway in additional indications.

Beyond regulatory momentum, pediatric and non-malignant blood disorder indications are actively being explored for Zemcelpro. ExCellThera's Enhance program aims to leverage UM171 not just for cord blood expansion but also to improve gene-modified stem cells and CAR-T cell products.

As Zemcelpro continues to make headway, it solidifies ExCellThera's position as one of the companies leading the way in the growing field of stem cell therapy. The approval of Zemcelpro in the European Union (EU) targets the challenge of donor availability in transplant medicine, offering hope for those in need of a life-saving transplant.

EU welcomes the debut of Zemcelpro, a revolutionary blood cord expansion therapy